Aditxt Management
Management criteria checks 3/4
Aditxt's CEO is Amro Albanna, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $519.23K, comprised of 83.2% salary and 16.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $1.84. The average tenure of the management team and the board of directors is 3.9 years and 5.2 years respectively.
Key information
Amro Albanna
Chief executive officer
US$519.2k
Total compensation
| CEO salary percentage | 83.2% |
| CEO tenure | 7.9yrs |
| CEO ownership | 0.00007% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$43m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | US$519k | US$432k | -US$33m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$500k | US$500k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$280k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$252k | US$252k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$2m | US$252k | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$5m |
| Dec 31 2018 | US$180k | US$180k | -US$6m |
| Dec 31 2017 | US$198k | US$51k | -US$852k |
Compensation vs Market: Amro's total compensation ($USD519.23K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Amro's compensation has increased whilst the company is unprofitable.
CEO
Amro Albanna (54 yo)
7.9yrs
Tenure
US$519,233
Compensation
Mr. Amro A. Albanna has been Chief Executive Officer and a Director of Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) since 2017 and serves as its Chairman of the Board and served as its Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.9yrs | US$519.23k | 0.000070% $ 1.8 | |
| Co-Founder | 7.9yrs | US$358.84k | 0.00011% $ 2.9 | |
| Chief Financial Officer | 3.3yrs | US$381.45k | 0.000030% $ 0.8 | |
| Chief Mergers & Acquisitions Officer | 2.7yrs | US$390.33k | 0.000030% $ 0.8 | |
| Chief Operating Officer | 4.4yrs | no data | 0.000020% $ 0.5 | |
| Director of Human Resources | 3.9yrs | no data | no data | |
| Senior Vice President of Clinical Development – Transplantation | 3.9yrs | no data | no data | |
| Senior Vice President of Preclinical Research & Discovery | 2.9yrs | no data | no data |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Management: ADTX's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.9yrs | US$519.23k | 0.000070% $ 1.8 | |
| Co-Founder | 7.9yrs | US$358.84k | 0.00011% $ 2.9 | |
| Independent Director | 4.4yrs | US$3.86k | 0.000010% $ 0.3 | |
| Independent Director | 1.1yrs | no data | 0.000050% $ 1.3 | |
| Independent Director | 6yrs | US$15.00k | 0.000010% $ 0.3 | |
| Director | less than a year | no data | no data |
5.2yrs
Average Tenure
61yo
Average Age
Experienced Board: ADTX's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:48 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aditxt, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |